Kynam Capital Management, LP Biocryst Pharmaceuticals Inc Transaction History
Kynam Capital Management, LP
- $1.19 Billion
- Q1 2025
A detailed history of Kynam Capital Management, LP transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Kynam Capital Management, LP holds 8,928,523 shares of BCRX stock, worth $78.2 Million. This represents 5.64% of its overall portfolio holdings.
Number of Shares
8,928,523
Previous 9,085,368
1.73%
Holding current value
$78.2 Million
Previous $68.3 Million
1.99%
% of portfolio
5.64%
Previous 4.33%
Shares
10 transactions
Others Institutions Holding BCRX
# of Institutions
294Shares Held
177MCall Options Held
721KPut Options Held
489K-
Vanguard Group Inc Valley Forge, PA21.7MShares$190 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$175 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.7MShares$76.2 Million1.06% of portfolio
-
State Street Corp Boston, MA7.81MShares$68.4 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY7.21MShares$63.2 Million0.11% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.63B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...